提升期望:在心力衰竭中使用维里西瓜特,减少喷射分数
Pushpraj Patel1, Anjeney Mishra1, Sachin Madhavrao Gawande1
1Department of Cardiology, Golden Heart Hospital, Jabalpur, Madhya Pradesh, India.
Journal of pharmacy & bioallied sciences
|February 10, 2025
概括
一种新疗法Vericiguat可能会改善心力衰竭 (HF) 患者的治疗结果. 这项研究表明, vericiguat与指导指导医疗疗 (GDMT) 结合,可以减少C期高血压的住院治疗和改善射出分数 (EF).
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 减少喷射分数 (HF-rEF) 的心力衰竭是致病率和死亡率的重要原因.
- 指南导向医学治疗 (GDMT) 是HF管理的基石,但许多患者仍然有症状.
研究的目的:
- 为了评估 vericiguat作为C阶段心力衰竭和减少喷射分数的患者的辅助治疗的疗效.
- 评估 vericiguat对死亡率,心力衰竭入院和喷射率的影响.
主要方法:
- 一项观察性队列研究包括100名患有C期HF和EF<40%的患者.
- 患者被分为两组: vericiguat加GDMT (n=48) 和单独使用GDMT (n=52).
- 在6个月内评估的主要结局包括死亡率,HF入院率和EF变化.
主要成果:
- 输血组的死亡率较低 (10.4%与17.3%相比),HF病例减少 (25.0%与38.5%相比).
- 每名患者的平均HF入院次数在接受治疗的患者组显着较低 (0.7对1.2,P=0.03).
- 射出分数在接受 vericiguat 的情况下得到了显著的改善 (+5.1% vs +2.3%,P<0.01).
结论:
- 韦里西瓜特似乎是一个有前途的辅助疗法,用于管理降低EF的C期HF患者.
- 需要进行更大规模的随机对照试验来证实这些发现,并确定输血瓜在HF治疗中的作用.
更多相关视频
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
8.4K
09:20Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
6.4K
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
374
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
374
01:26Heart Failure Drugs: Inotropic Agents
504
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
504
01:22Heart Failure Drugs: Diuretics
338
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
338
01:22Heart Failure Drugs: β-Blockers
311
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
311
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
131
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
131
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
573
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
573